Insider Selling: Vaxcyte, Inc. (NASDAQ:PCVX) CFO Sells $710,240.00 in Stock

Vaxcyte, Inc. (NASDAQ:PCVX) CFO Andrew Guggenhime sold 8,000 shares of Vaxcyte stock in a transaction dated Wednesday, December 18th. The stock was sold at an average price of $88.78, for a total value of $710,240.00. Following the transaction, the chief financial officer now owns 109,491 shares of the company’s stock, valued at $9,720,610.98. The trade was a 6.81 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Andrew Guggenhime also recently made the following trade(s):

• On Friday, October 18th, Andrew Guggenhime sold 42,000 shares of Vaxcyte stock. The shares were sold at an average price of $115.39, for a total value of $4,846,380.00.

Vaxcyte Stock Up 0.4 %

Shares of NASDAQ:PCVX opened at $86.53 on Friday. Vaxcyte, Inc. has a 12-month low of $53.83 and a 12-month high of $121.06. The company’s 50 day moving average price is $98.70 and its two-hundred day moving average price is $92.28. The firm has a market cap of $10.78 billion, a PE ratio of -18.81 and a beta of 0.94.

Vaxcyte (NASDAQ:PCVX) last issued its quarterly earnings results on Tuesday, November 5th. The company reported ($0.83) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.10) by $0.27. During the same period in the prior year, the firm earned ($0.91) earnings per share. On average, research analysts expect that Vaxcyte, Inc. will post -4.14 EPS for the current year.

Institutional Trading of Vaxcyte

Several large investors have recently modified their holdings of the stock. Janus Henderson Group PLC raised its stake in Vaxcyte by 23.1% in the third quarter. Janus Henderson Group PLC now owns 10,921,896 shares of the company’s stock valued at $1,247,954,000 after purchasing an additional 2,052,989 shares in the last quarter. RA Capital Management L.P. raised its position in shares of Vaxcyte by 5.9% in the 3rd quarter. RA Capital Management L.P. now owns 8,689,190 shares of the company’s stock valued at $992,914,000 after buying an additional 485,436 shares in the last quarter. State Street Corp lifted its holdings in shares of Vaxcyte by 1.1% during the 3rd quarter. State Street Corp now owns 3,405,743 shares of the company’s stock worth $389,174,000 after acquiring an additional 38,596 shares during the period. Franklin Resources Inc. boosted its position in shares of Vaxcyte by 13.2% during the 3rd quarter. Franklin Resources Inc. now owns 2,786,335 shares of the company’s stock worth $315,162,000 after acquiring an additional 324,560 shares in the last quarter. Finally, Geode Capital Management LLC boosted its position in shares of Vaxcyte by 10.6% during the 3rd quarter. Geode Capital Management LLC now owns 2,700,782 shares of the company’s stock worth $308,675,000 after acquiring an additional 259,010 shares in the last quarter. 96.78% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on PCVX shares. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Vaxcyte in a report on Wednesday, November 6th. The Goldman Sachs Group started coverage on shares of Vaxcyte in a research note on Friday. They set a “buy” rating and a $135.00 target price for the company. BTIG Research upped their price target on shares of Vaxcyte from $98.00 to $160.00 and gave the company a “buy” rating in a research note on Tuesday, September 3rd. Needham & Company LLC restated a “buy” rating and set a $140.00 price objective on shares of Vaxcyte in a research report on Wednesday, November 6th. Finally, Mizuho upped their target price on Vaxcyte from $113.00 to $163.00 and gave the company an “outperform” rating in a research report on Tuesday, September 10th. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $145.71.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.